Cargando…

COVID-19 and immune checkpoint inhibitors: initial considerations

COVID-19 infections are characterized by inflammation of the lungs and other organs that ranges from mild and asymptomatic to fulminant and fatal. Patients who are immunocompromised and those with cardiopulmonary comorbidities appear to be particularly afflicted by this illness. During pandemic cond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sullivan, Ryan J, Johnson, Douglas B, Rini, Brian I, Neilan, Tomas G, Lovly, Christine M, Moslehi, Javid J, Reynolds, Kerry L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246104/ https://www.ncbi.nlm.nih.gov/pubmed/32434790 http://dx.doi.org/10.1136/jitc-2020-000933

Ejemplares similares

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
por: Neilan, Tomas G., et al.
Publicado: (2018)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
por: Wright, Jordan J., et al.
Publicado: (2018)

Renin–angiotensin–aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors
por: Drobni, Zsofia D., et al.
Publicado: (2022)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors
por: Odabasi, Zekaver, et al.
Publicado: (2020)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019)

Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease
por: Chau, Charlene Y. C., et al.
Publicado: (2020)

Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients: Ready for Prime Time?
por: Aras, Mandar A., et al.
Publicado: (2020)

Immune Checkpoint Inhibitors’ Effects on Calcified Aortic Plaques in Melanoma Survivors: A Retrospective Cohort Study
por: Turker, Isik, et al.
Publicado: (2023)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor–Associated Myocarditis
por: Drobni, Zsofia D., et al.
Publicado: (2020)

Smoldering myocarditis following immune checkpoint blockade
por: Norwood, Timothy G., et al.
Publicado: (2017)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
por: Awadalla, Magid, et al.
Publicado: (2019)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial
por: Rini, Brian I., et al.
Publicado: (2022)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
por: Jardim, Denis L., et al.
Publicado: (2018)

Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
por: Drobni, Zsofia D, et al.
Publicado: (2021)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
por: Tawbi, Hussein A, et al.
Publicado: (2023)

Considerations for treatment duration in responders to immune checkpoint inhibitors
por: Marron, Thomas U, et al.
Publicado: (2021)

Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms
por: Rhee, John Y, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
por: Chen, Yu-Wei, et al.
Publicado: (2021)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach
por: Heilbroner, Samuel Peter, et al.
Publicado: (2021)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review
por: Suero-Abreu, Giselle Alexandra, et al.
Publicado: (2022)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
por: Guidon, Amanda C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t47mfajvg10tos8ocjsn1v72lp